Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773944 | 0.82 | BCHE (0.42) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL773625 | 0.81 | FTO (0.50) | HSP90AA1CDK5CDK5R1MAPTTDP1 | |
| SCHEMBL441633 | 0.81 | PABPC1 (0.50) | HSP90AA1CDK5CDK5R1MAPTALDH1A1 | |
| SCHEMBL768650 | 0.80 | MAPT (0.51) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL773238 | 0.79 | POLB (0.57) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL441279 | 0.79 | TDP1 (0.47) | HSP90AA1CDK5CDK5R1MAPTTDP1 | |
| SCHEMBL773871 | 0.78 | HTR1A (0.45) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL768407 | 0.78 | MAPT (0.47) | MAPTTDP1ALDH1A1MEN1POLB | |
| SCHEMBL767951 | 0.78 | MAPT (0.44) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL13692309 | 0.78 | POLB (0.49) | MAPTMEN1POLBKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | HSP90AA1 1311/4885CDK5 485/4885CDK5R1 980/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | HSP90AA1 1311/4885CDK5 485/4885CDK5R1 980/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HSP90AA1 1304/4885CDK5 189/4885CDK5R1 354/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | HSP90AA1 1304/4885CDK5 189/4885CDK5R1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.